Bluejay Therapeutics

top of page

SF Healthcare Week: Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

She discusses the profile of the drug, which is currently in a phase 3 study, and the data Bluejay had previously presented on it. Plus, her advice for other entrepreneurs who might be fielding bids.

Company News

Jan 13

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

SF Healthcare Week: Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

Follow BiotechTV

Sponsors

Sponsor Spotlight